APP Pharmaceuticals releases preservative-free Methotrexate; Ranbaxy selling generic Lipitor in Europe;

> APP Pharmaceuticals ($APPX), which two weeks ago received FDA approval to make preservative-free Methotrexate at its manufacturing facility in Melrose Park, IL, has released 35,000 vials of Methotrexate Injection, USP, and 10,000 vials of preservative-free Methotrexate Injection, USP, which should soon be available to clinicians to ease shortage issues. Story

> Per its agreement with Pfizer ($PFE), Ranbaxy Laboratories ($RANBXY.NS) is selling a generic version of Lipitor in Germany, Italy, Sweden and the Netherlands. Story

> Endo Pharmaceuticals Holdings ($ENDP), maker of the Opana ER painkiller, will ask shareholders to approve a name change to Endo Health Solutions Inc. Release

> Merck KGaA ($MRK.DE) has donated to the Zambian Health Ministry 5 mobile labs to be used to detect counterfeit medications. Release  

> Ann Arbor, MI.-based Rubicon Genomics, has selected Velesco Pharmaceutical Services, which has a 10,000 square foot manufacturing facility in nearby Kalamazoo, MI, to manufacture breast cancer diagnostics kits Rubicon is providing to Agendia, a molecular diagnostics company. Release  

> Chemist Cheng Yi Liang, who worked for the FDA's Center for Drug Evaluation and Research, was sentenced to 5 years in prison for trading on insider information to make $3.78 million. Story

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.